RecruitingPulmonary HypertensionInterstitial Lung Disease (ILD)Lung Diseases
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Sponsor: Pulmovant, Inc.
You may qualify if…
- ✓ Participants willing and able to provide informed consent
- ✓ Participants on inhaled treprostinil
- ✓ Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
- ✓ 1. Idiopathic interstitial pneumonia (IIP)
- ✓ 2. Chronic hypersensitivity pneumonitis
- ✓ 3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
- ✓ Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
- ✓ Ability to perform 6MWD ≥100 meters.
You may not qualify if…
- ✕ Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
- ✕ Exacerbation of underlying lung disease within 28 days prior to randomization.
- ✕ Initiation of pulmonary rehabilitation within 28 days prior to randomization.
- ✕ Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- ✕ History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
- ✕ Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.
- ✕ Note: Other inclusion and exclusion criteria may apply.
Where it's recruiting
Florida
Kissimmee
Source: ClinicalTrials.gov · NCT07333183 · last updated 2026-04-22